FDA approves DNA testing company 23andMe's hereditary CRC test — 4 insights

The FDA awarded DNA testing company 23andMe clearance to include risk reports associated with hereditary colorectal cancer in its testing suite.

What you should know:

1. 23andMe will soon include information on genetic variants that can influence MUTYH-associated polyposis in its reports.

2. If customers opt-in to the report, 23andMe is providing an education module to help them interpret the results and understand the limitations of the report.

3. Hereditary CRC cases account for about 5 percent of all CRC cases, the company said.

4. Company CEO Anne Wojcicki said, "We are committed to giving people affordable and direct access to important health information that can impact their lives. We believe improved access to genetic testing and health information will help people engage in their own health."

More articles on gastroenterology:
How ASC price transparency relates to value-based care, M&A activity & more: 4 insights
ACS grants Children's Minnesota surgery center certification — 3 insights
HCA announces $1B public offering that could be used for acquisitions — 4 insights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months